Liraglutide and Renal Outcomes in Type 2 Diabetes
Top Cited Papers
Open Access
- 31 August 2017
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (9), 839-848
- https://doi.org/10.1056/nejmoa1616011
Abstract
In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown.Keywords
This publication has 31 references indexed in Scilit:
- Diabetes and Cause-Specific Mortality in Mexico CityThe New England Journal of Medicine, 2016
- Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptinKidney International, 2015
- Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesKidney International, 2015
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potentialKidney International, 2014
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice GuidelineAnnals of Internal Medicine, 2013
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetesKidney International, 2013
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes MellitusArchives of Internal Medicine, 2012
- Nephropathy in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998